Fungal infections in patients with cystic fibrosis
DOI:
https://doi.org/10.6016/ZdravVestn.1552Keywords:
cystic fbrosis, fungal infections, aspergillus, candida, scedosporiumAbstract
In the last two decades prevalence of fungal infections is increasing for various reasons. One of them is the advance of medical science and the associated longer life expectancy in some patient groups. This includes cystic fibrosis patients who encounter fungal diseases already in their childhood. Fungal pathogens isolated in high frequencies from the respiratory tract include Aspergillus fumigatus, Candida albicans and Scedosporium apiospermum. In the case of cystic fibrosis, these organisms normaly colonise the respiratory and intestinal mucosae and can cause hipersensitivity reactions and invasive diseases. The fungus-patient interactions are complex and depend on several different factors which determine what course will the colonisation/infection take.
Downloads
References
Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fbrosis. Clin Microbiol Rev. 2002;5(2):194–222.
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fbrosis. Pediatr Pulmonol. 2002;34(2):91–100.
Liu JC, Modha EM, Gaillard EA. What is the clinical signifcance of flamentous fungi positive sputum cultures in patients with cystic fbrosis? J Cys Fibros. 2013;12(3):187–93.
Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP. Prevalence and risk factors for recovery of flamentous fungi in individuals with cystic fbrosis. J Cyst Fibros. 2010;9(2):110–6.
Chotirmall SH, Greene CM, McElvaney NG. Candida species in cystic fbrosis: a road less travelled. Med Mycol. 2010;48.Supp 1:S114-24.
Chotirmall SH, McElvaney NG. Fungi in the cystic fbrosis lung: bystanders or pathogens? Int J Biochem Cell Biol. 2014;52:161–73.
LiPuma JJ. Te changing microbial epidemiology in cystic fbrosis. Clin Microbiol Rev. 2010;23(2):299–323.
Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, et al. Antibiotic management of lung infections in cystic fbrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. Ann Am Torac Soc. 2014;11(8):1298–306.
Lyon A, Gun E, Haworth CS, Bilton D. Is genital Candida infection a signifcant problem for adults with cystic fbrosis. J Cyst Fibros. 2004;3:S99.
Čižman M, Beović B. Kako predpisujemo protimikrobna zdravila v bolnišnicah. 2. izd. Ljubljana: Sekcija za protimikrobno zdravljenje Slovenskega zdravniškega društva; 2013. p. 148–53.
The Sanford Guide to Antimicrobial Terapy, Web Edition [cited 3.8.2016].Available froM. http://webedition.sanfordguide.com/.
Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick, & Adelberg‘s Medical Microbiology. 26th ed. New York: Lange medical books; 2013.
Global action found for fungal infections (GAFFI). 2016 [cited 4.5.2016]. Available from: http://www.gaf.org/.
Corneley OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012:non-neutropenic adult patients. Clin Microbiol Infect. 2012;18.s7:19–37
Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richardson MD, Denning DW. Novel immunologic classifcation of aspergillosis in adult cystic fbrosis. J Allergy Clin Immunol. 2013;132(3):560–6.
Maturu VN, Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fbrosis: systematic review and meta-analysis. Clin Exp Allergy. 2015;45(12):1765–78.
Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol. 2012;129(2):280–91
Moss RB. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fbrosis. Curr Opin Pulm Med. 2010;16(6) 598–603.
Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fbrosis. Clin Dev Immunol. 2011;843763.
Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology. 7th ed: Philadelphia: Mosby: Elsevier; 2013
Kosmidis C, Denning DW. Te clinical spectrum of pulmonary aspergillosis. Torax. 2015;70(3):270–7.
Wong R, Wong M, Robinson PD, Fitzgerald DA. Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fbrosis. Paediatr Respir Rev. 2013;14(1):22–4.
de Benedictis FM, Bush A. Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med. 2012;185(1):12–23.
Tanou K, Elias Z, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fbrosis: a synthesis of published evidence. Pediatr Pulmonol. 2014;49(5):503–7.
Moreira AS, Silva D, Reis Ferreira A, Delgado L. Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis: a systematic review. Clin Exp Allergy. 2014;44(10):1210–27.
Chishimba L, Langridge P, Powell G, Niven RM, Denning DW. Efcacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). J Asthma. 2015;52(3):289–95.
Gernez Y, Walters J, Mirković B, Gillian ML, Colleen DE, Davies ZA, et al. Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fbrosis. Eur Respir J. 2015;ERJ-01068.
Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11.
Luong ML, Chaparro C, Stephenson A, Rotstein C, Singer LG, Waters V, et al. Pretransplant Aspergillus colonization of cystic fbrosis patients and the incidence of post–lung transplant invasive aspergillosis. Transplantation. 2014;97(3):351–7.
Latgé JP. Te pathobiology of Aspergillus fumigatus. Trends Microbiol. 2001;9(8):382–9.
Felton IC, Simmonds NJ. Aspergillus and cystic fbrosis: old disease–new classifcations. Curr Opin Pulm Med. 2014;20(6):632–8.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised defnitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813–21.
Shoseyov D, Brownlee KG, Conway SP, Kerem E. Aspergillus bronchitis in cystic fbrosis. Chest. 2006;130(1):222–6.
Chrdle A, Mustakim S, Bright-Tomas RJ, Baxter CG, Felton T, Denning DW. Aspergillus bronchitis without signifcant immunocompromise. Ann N Y Acad Sci. 2012;1272(1):73–85.
Sudhadham M, Sihanonth P, Sivichai S, Chaiyarat R, Dorrestein GM, Menken SBJ, De Hoog GS, et. al. Te neurotropic black yeast Exophiala dermatitidis has a possible origin in the tropical rain forest. Stud Mycol. 2008;61:145–55.
Zalar P, Novak M, De Hoog GS, Gunde-Cimerman N. Dishwashers–a man-made ecological niche accommodating human opportunistic fungal pathogens. Fungal Biol. 2011;115.10:997–1007.
Kenney RT, Kwon-Chung KJ, Waytes AT, Melnick, DA, Pass HI, Merino MJ, et al. Successful treatment of systemic Exophiala dermatitidis infection in a patient with chronic granulomatous disease. Clin Infect Dis. 1992;14(1):235–42.
Kusenbach G, Skopnik H, Haase G, Friedrichs F, Döhmen H. Exophiala dermatitidis pneumonia in cystic fbrosis. Eur J Pediatr. 1992;151(5):344–6.
Diemert D, Kunimoto D, Sand C, Rennie R. Sputum isolation of Wangiella dermatitidis in patients with cystic fbrosis. Scand J Infect Dis. 2001;33(10):777–9.
Lebecque P, Leonard A, Huang D, Reychler G, Boeras A, Leal T, Symoens F. Exophiala (Wangiella) dermatitidis and cystic fbrosis–Prevalence and risk factors. Med Mycol. 2010;48 Supp 1:S4–9.
Kondori N, Gilljam M, Lindblad A, Jönsson B, Moore ERB, Wennerås C. High rate of Exophiala dermatitidis recovery in the airways of patients with cystic fbrosis is associated with pancreatic insufciency. J Clin Microbiol. 2011;49(3):1004–9.
Blaschke-Hellmessen R, Lauterbach I, Paul KD, Tintelnot K, Weissbach G. Detection of Exophiala dermatitidis (Kano) De Hoog 1977 in septicemia of a child with acute lymphatic leukemia and in patients with cystic fbrosis. Mycoses. 1994;37 Suppl 1:89–96.
Masoud-Landgraf L, Badura A, Eber E, Feierl G, Marth E, Buzina W. Modifed culture method detects a high diversity of fungal species in cystic fbrosis patients. Med Mycol. 2014;52(2):179–86.
Lackner M, de Hoog GS, Yang L, Ferreira Moreno L, Ahmed SA, et al. Proposed nomenclature for Pseudallescheria, Scedosporium and related genera. Fungal Divers. 2014;67(1):1–10.
Bernhardt A, Sedlacek L, Wagner S, Schwarz C, Würstl B, Tintelnot K. Multilocus sequence typing of Scedosporium apiospermum and Pseudallescheria boydii isolates from cystic fbrosis patients. J Cyst Fibros. 2013;12(6):592–8.
Zouhair R, Rougeron A, Razafmandimby B, Kobi A, Bouchara JP, Giraud S. Distribution of the different species of the Pseudallescheria boydii/Scedosporium apiospermum complex in French patients with cystic fbrosis. Med Mycol. 2013;51(6):603–13.
Morio F, Horeau-Langlard D, Gay-Andrieu F, Talarmin JP, Haloun A, Treilhaud M, et al. Disseminated Scedosporium/Pseudallescheria infection afer double-lung transplantation in patients with cystic fbrosis. J Clin Microbiol. 2010;48(5):1978–82.
Borghi E, Iatta R, Manca A, Montagna MT, Morace G. Chronic airway colonization by Scedosporium apiospermum with a fatal outcome in a patient with cystic fbrosis. Med Mycol. 2010;48 Suppl: S108–13.
Cimon B, Carrère J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical signifcance of Scedosporium apiospermum in patients with cystic fbrosis. Eur J Clin Microbiol Infect Dis. 2000;19(1):53–6.
Sahi H, Avery RK, Minai OA, Hall G, Mehta AC, Raina P, et al. Scedosporium apiospermum (Pseudoallescheria boydii) infection in lung transplant recipients. J Heart Lung Transplant. 2007;26(4):350–6.
Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanhiera M. In vitro activity of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and moulds. J Clin Microbiol. 2013;JCM-00863.
Tortorano AM, Richardson M, Roilides E, van Diepeningenet A, Caira M, Munoz P, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp, Scedosporium spp. and others. Clin Microbiol Infect. 2014;20(s3):27–46.
Houbraken J, Spierenburg H, Frisvad JS. Rasamsonia, a new genus comprising thermotolerant and thermophilic Talaromyces and Geosmithia species. Antonie van Leeuwenhoek. 2012;101(2):403–21.
Giraud S, Favennec L, Bougnoux ME, Bouchara JP. Rasamsonia argillacea species complex: taxonomy, pathogenesis and clinical relevance. Future Microbiol. 2013;8(8):967–78.
Steinmann J, Giraud S, Schmidt D, Sedlacek L, Hamprecht A, Houbraken J, et al. Validation of a novel real-time PCR for detecting Rasamsonia argillacea species complex in respiratory secretions from cystic fbrosis patients. New Microbes New
Infect. 2014;2(3):72–8.
Matos T, Cerar Kišek T, Praprotnik M, Krivec U, Pirš M. First recovery of Rasamsonia argillacea species complex isolated in adolescent patient with cystic fbrosis in Slovenia–case report and review of literature. Mycoses. 2015;58(8):506–10.
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
